Abstract
Background Viremia is a critical factor in understanding the pathogenesis of dengue infection, but limited data exist on viremia kinetics. This study aimed to investigate the kinetics of viremia and its effects on subsequent platelet count, severe dengue, and plasma leakage.
Methods We pooled data from three studies conducted in Vietnam between 2000 and 2016, involving 2340 dengue patients with daily viremia measurements and platelet counts after symptom onset. Viremia kinetics were assessed using a random effects model that accounted for left-censored data. The effects of viremia on subsequent platelet count and clinical outcomes were examined using a landmark approach with a random effects model and logistic regression model with generalized estimating equations, respectively. The rate of viremia decline was derived from the model of viremia kinetics. Its effect on the clinical outcomes was assessed by logistic regression models.
Results Viremia levels rapidly decreased following symptom onset, with variations observed depending on the infecting serotype. DENV-1 exhibited the highest mean viremia levels during the first 5-6 days, while DENV-4 demonstrated the shortest clearance time. Higher viremia levels were associated with decreased subsequent platelet counts from day 6 onwards. Elevated viremia levels on each illness day increased the risk of developing severe dengue and plasma leakage. However, the effect size decreased with later illness days. A more rapid decline in viremia is associated with a reduced risk of the clinical outcomes.
Conclusions This study provides comprehensive insights into viremia kinetics and its effect on subsequent platelet count and clinical outcomes in dengue patients. Our findings underscore the importance of measuring viremia levels during the early febrile phase for dengue studies and support the use of viremia kinetics as outcome for phase-2 dengue therapeutic trials.
Competing Interest Statement
Thomas Jaenisch: reports receiving personal fees as members of the Roche Pharmaceuticals Advisory Board on Severe Dengue, outside the submitted work. Sophie Yacoub: reports receiving personal honorarium for attending the Novartis dengue drug ad board meeting and Takeda dengue education symposium, outside the submitted work. Bridget Wills: reports receiving personal fees a) as a member of the Roche Advisory Board on Severe Dengue and b) as a member of the Data Monitoring and Adjudication Committees for the Takeda dengue vaccine trials, both outside the remit of the submitted work. The other authors declare that no competing interests exist.
Funding Statement
Cameron P. Simmons: Wellcome Trust (grant ref no 084368/Z/07/Z) Bridget A. Wills: Wellcome Trust (grant ref no 077078/Z/05/Z, 077078/Z/05/A, and 089276/B/09/Z) Thomas Jaenisch: European Union Seventh Framework Programme (grant ref no FP7-281803 IDAMS) Ronald B. Geskus and Sophie Yacoub: Wellcome Trust (grant ref no 106680/Z/14/Z and 225167/Z/22/Z) The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Oxford Tropical Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The abstract, introduction, statistical analysis, and results updated to add the effect of the rate of decline in viremia on the clinical outcomes; Figure 3 revised; Figure 5 revised; Figure 6 added; Supplementary file updated.
Data Availability
The data that support the findings of this study are available from the corresponding author, (Nguyen Lam Vuong), upon reasonable request.
